Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06847438

Tailored Electronic Intervention to Improve Therapy in a Diverse Cohort of Patients With Heart Failure

Led by Emory University · Updated on 2026-04-14

4000

Participants Needed

4

Research Sites

62 weeks

Total Duration

On this page

Sponsors

E

Emory University

Lead Sponsor

M

Merck Sharp & Dohme LLC

Collaborating Sponsor

AI-Summary

What this Trial Is About

Recent medical guidelines for the management of heart failure (HF) have established a combination of specific classes of medications as the best treatment for patients with heart failure with reduced ejection fraction (HFrEF). However, studies have shown that these medications, known together as guideline-directed medical therapy (GDMT), are not being used in clinical practice less often than they could be. Several tools to promote broader use of these treatments (including patient checklists) have shown promise for increasing use of GDMT. However, these tools have not been broadly implemented within large health systems. The goal of this study is to see if using these tools broadly within cardiology clinics will increase the use of GDMT. This study is important because it could help improve the use of GDMT, which may lead to improved patient care and outcomes.

CONDITIONS

Official Title

Tailored Electronic Intervention to Improve Therapy in a Diverse Cohort of Patients With Heart Failure

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Ejection fraction (EF) less than or equal to 40% by echocardiogram performed in the prior 18 months
  • Diagnosis of heart failure
Not Eligible

You will not qualify if you...

  • Heart failure etiology for which GDMT is not indicated, including hypertrophic or restrictive cardiomyopathy, constrictive pericarditis, or complex congenital heart disease
  • End-stage heart failure requiring continuous inotrope infusion, heart transplant, or left ventricular assist device
  • Estimated glomerular filtration rate (eGFR) less than 15 mL/min/1.73m2
  • Any other conditions likely to alter patient's status over 6 months, indicated by active hospice status

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Emory Saint Joseph's Hospital

Atlanta, Georgia, United States, 30308

Actively Recruiting

2

Emory University Hospital Midtown

Atlanta, Georgia, United States, 30308

Actively Recruiting

3

Emory University Hospital

Atlanta, Georgia, United States, 30322

Actively Recruiting

4

Emory Johns Creek Hospital

Johns Creek, Georgia, United States, 30097

Actively Recruiting

Loading map...

Research Team

N

Neal W Dickert, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

HEALTH_SERVICES_RESEARCH

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here